# Aclaris Therapeutics Inc. (ACRS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.17, market value $908 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Aclaris Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 110.5×**. Each dollar of revenue is priced at 110.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 6.9×**. The shares trade at 6.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -6.8%** (5-yr avg -29.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Net margin: -829.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -63.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -72.7%**. Return on all capital, debt included, is -72.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -47.2%**. Each dollar of assets produces -47.2% of profit.

## Growth
- **Revenue growth (1 yr): -58.2%** (3-yr -35.9%/yr, 5-yr 3.8%/yr). Revenue fell 58.2% over the last year, against 3.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 69.0%**. Earnings per share rose 69.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 3.36** (quick 3.36). Current assets cover the next year's liabilities 3.36 times.
- **Altman Z-score: 9.38**. A Z-score of 9.38 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Aclaris Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Aclaris Therapeutics Inc.; the consensus is strong_buy, with an average price target of $10.20 (+65% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 198.1%** (YTD 105.0%, 3-mo 41.5%). The shares are up 198.1% over twelve months including dividends.
- **From 52-week high: -6.5%** (254.6% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.59** (volatility 97%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ACRS · Page: https://foliofundamentals.com/stocks/acrs

Not investment advice.